JNJ Stock Price Surges Past Expectations Amid Biosimilar Competition and Talc Litigation Developments

Johnson & Johnson (JNJ) has seen its stock price return 59.9% over the past year, outperforming the S&P 500's 21.1% gain. The company cites a clean story behind this success, including the arrival and absorption of biosimilar competition in STELARA, as well as the proposed settlement framework for talc litigation. However, management noted that these factors alone do not explain the size of the stock price increase.

The company reported operational sales growth of 5.6% in Q2 2026, despite a 55.7% decline in STELARA sales due to biosimilars. Excluding STELARA, JNJ's growth was double digits, with TREMFYA growing 71%. Management raised the full-year 2026 operational sales outlook to 6.5% to 7.1%, or $100.6 billion, which includes a 53rd week in the financial calendar.

The company is on track to pass $100 billion in annual revenue for the first time in its 140-year history. Revenue over the trailing twelve months is up 8.1% year-over-year, but reported profitability declined due to normalization after a one-off gain from the Kenvue separation. Operating margin currently sits at 26.8%, which reflects core business profitability holding steady.